Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol-Myers

McKesson

Bristol Myers Squibb, Cardinal Health, and McKesson are all underpriced.

3 Healthcare Stocks With a Solid Bottom Line -- and a Dividend

Wolf's Corona Discounts: Cardinal Health

Bank of America

AT&T

These stocks all yield more than 3% right now -- and the prices are bargains too.

3 Embarrasingly Cheap Dividend Stocks You Can Buy Now

Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.

Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - April 23, 2020

Cardinal Health: A Dividend Aristocrat Still On Sale

Avid Technology

EMCOR Group

Can screening for Zacks Strong Buy stocks help investors find quality earnings during this uncertain economic time?

How to Find Value Stocks During the Coronavirus Crisis

DISH Network

Synopsys

T-Mobile US

Here is a sneak peek into four S&P 500 stocks, which hold promise amid coronavirus chaos.

4 S&P 500 Stocks to Buy This Coronavirus-Hit Earnings Season

In the latest trading session, Cardinal Health (CAH) closed at $50.07, marking a -1.22% move from the previous day.

Cardinal Health (CAH) Stock Moves -1.22%: What You Should Know

Amgen

Costco

Enphase Energy

LogMeIn

Netflix

Coronavirus outbreak-induced global lockdowns are making recession inevitable. Here are six recession-resistant stocks including Netflix (NFLX) to beat COVID-19 induced recession woes.

6 Recession-Proof Picks Amid Coronavirus-Led "The Great Lockdown"

Bull of the Day: Cardinal Health (CAH)

Huron Consulting Group

Amplify Mobile Payments ETF

iShares U.S. Home Construction ETF

iShares U.S. Healthcare ETF

Kraft Heinz

Meritage Homes

Telephone and Data Systems

Consumer Staples Select Sector SPDR Fund

Utilities Select Sector SPDR Fund

First-quarter results are likely to be bleak, given that the coronavirus outbreak are weighing on corporate profits. However, there are still some bright spots.

Any Bright Spot in Q1 Earnings? Sector ETFs & Stocks to Buy

Atlas Air Worldwide

AmerisourceBergen

Allegheny Technologies

CVS Health

Brokers have lot more information on a company's profile and its prospects than individual investors as the former attends conference calls, company presentations and interact with management as well.

5 Broker-Friendly Stocks Amid Coronavirus-Led Pandemonium

As of late, it has definitely been a great time to be an investor in Cardinal Health

Cardinal Health's Shares March Higher, Can It Continue?

Chemed

Dropbox

Royal Philips

Although the death toll continues to go up in the United States, the curves related to hospitalization, intensive-care check-ins and intubations are gradually flattening.

U.S. Economy Likely to Reopen in May: 5 Top Growth Picks

Exxon Mobil

Cheap, time-tested, high-yield dividend stocks? Yes, please!

3 Dividend Aristocrats That Are Screaming Buys

AbbVie

Rocky Brands

Top Ranked Income Stocks to Buy for April 8th

Top Ranked Income Stocks to Buy for April 8th 2020

Cardinal Health (CAH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Cardinal Health (CAH) Stock Stands Out in a Strong Industry

Ampco-Pittsburgh

Booz Allen Hamilton Hld

Grocery Outlet

Want to try an out-of-the-box approach to earn handsome returns in the time of coronavirus? Tap these stocks with explosive relative price strength.

Focus on Relative Price Strength to Soften the Coronavirus Blows

DaVita

Ensign Group

Inmode Ltd

Integer Holdings

Here are 5 ways to make the most of a difficult market.

5 Stocks to Buy for 5 Good Reasons

IDEXX Laboratories

Thermo Fisher Scientific

Here are a few MedTech companies which have outperformed the S&P 500 index in the past two months.

Coronavirus Hits S&P 500: 4 MedTech Stocks That Fared Better

America Movil SAB de CV

TEGNA

Volatility is likely to persist in April as the panoptic impact of the coronavirus outbreak is yet to be realized in the United States and globally.

5 Top Value Stocks to Buy in a Volatile April

Medtronic

ResMed

COVID-19 has increased the demand for ventilators and personal protective equipment, which can aid these three companies at large.

3 Must-Buy Stocks as Coronavirus Cases Spike (Revised)

Cardinal Health: Future Dividend Aristocrat

Automatic Data Processing

Aflac

A. O. Smith

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Chubb

Colgate-Palmolive

Dover

In times of market turmoil, one group of stocks that investors can count on to deliver reliable income growth is the Dividend Aristocrats: an elite group of companies that have produced at least 25 consecutive years of dividend hikes.

19 Dividend Aristocrats That Have Gone on Deep Discount

News for Cardinal Health Stock (CAH)